Pembrolizumab (Keytruda®) accepted for restricted use within NHS Scotland for renal cell carcinoma

Pembrolizumab intravenous infusion in combination with axitinib, is approved for the first-line treatment of advanced renal cell carcinoma in adults, subject to a two-year clinical stopping rule.

Source:

Scottish Medicines Consortium